Saturday, February 27, 2010
Move over, MRSA!
This morning's New York Times has a piece by Andrew Pollack on healthcare associated infections. That in itself is not a surprise anymore since the general public is quite interested in the topic. What is surprising is that the article isn't about MRSA--it's about Acinetobacter and the lack of effective drugs to treat multidrug resistant gram-negative organisms. Could this be a harbinger that the fixation on MRSA is starting to wane? Pollack remains, to my knowledge, the only journalist that has linked the frenzy to culture inpatients for MRSA with big profits by the companies who manufacture the MRSA testing kits.
Subscribe to:
Post Comments (Atom)
OSHA! OSHA! OSHA!
In many parts of the country, as rates of COVID-19 are declining and vaccination coverage is increasing (albeit with substantial variati...
-
In many parts of the country, as rates of COVID-19 are declining and vaccination coverage is increasing (albeit with substantial variati... -
This is a guest post by Jorge Salinas, MD, Hospital Epidemiologist at the University of Iowa Hospitals & Clinics. There is virtually no...
-
I’m surprised that we can’t stop arguing about the modes of SARS-CoV-2 transmission, despite the fact that most experts (including our frie...
No comments:
Post a Comment
Thanks for submitting your comment to the Controversies blog. To reduce spam, all comments will be reviewed by the blog moderator prior to publishing. However, all legitimate comments will be published, whether they agree with or oppose the content of the post.